Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US) is GSK’s follow up to its respiratory blockbuster Advair/Seretide, but won’t come close to ...

Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone furoate and vilanterol) and Trelegy Ellipta (fluticasone furoate, umeclidinium ...

This cap would apply to all of GSK’s asthma and chronic obstructive pulmonary disease (COPD) inhalers, which include Advair Diskus, Advair HFA, Anoro Ellipta, Breo Ellipta and Trelegy Ellipta.

GSK plc GSK reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a ...

Fluticasone furoate, vilanterol 50/25mcg, 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. The ...

Wolff Olins has created the new brand identity for global healthcare company GSK (formerly GlaxoSmithKline), aiming to better express its focus on innovation. The agency was brought on board around 18 ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Incruse Ellipta (umeclidinium) is a brand-name inhaler prescribed for chronic obstructive pulmonary disease (COPD) in adults. As with other drugs, Incruse Ellipta can cause side effects ...

Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic inhaler ...